Prediction of Clinically Relevant Mutations in (MDS): A Report on Behalf of the MDS Clinical Research Consortium (CRC)
Sangmin Lee(Pohang TechnoPark (South Korea)), Gail J. Roboz(Cornell University), John Barnard(Cleveland Clinic Lerner College of Medicine), Amy E. DeZern(Johns Hopkins University), Mikkael A. Sekeres(University of Miami), Duane C. Hassane(AstraZeneca (Singapore)), Pinkal Desai(NewYork–Presbyterian Hospital), Ellen K. Ritchie(Cornell University), Jaroslaw P. Maciejewski(Cleveland Clinic), Felix Tavernier, David P. Steensma(Harvard University), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Rami S. Komrokji(Moffitt Cancer Center)
Cited by 0
Related Papers
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k